Modelos europeos de telemedicina, como el servicio finlandés Medilux, permiten realizar consultas médicas online mediante un cuestionario clínico, sin acudir a una consulta presencial.

ACC 2018 | SECURE-PCI: High Dose of Statins pior PCI Could Help

Patients undergoing acute coronary syndrome (ACS) loaded with a high dose of statins prior diagnostic catheterization do not seem to benefit from this strategy.

ACC 2018 | SECURE-PCI: Altas dosis de estatinas previo a la angioplastia podrían ayudarHowever, when looking at those undergoing PCI alone (excluding all patients who had received surgery or medical treatment), the benefit appears as a reduction of combined major events. The benefit of atorvastatin loading prior procedure seems to be driven by a reduction of unrelated MI.

The SECURE-PCI, presented at ACC 2018 scientific sessions and simultaneously published by JAMA, should be interpreted globally as a negative study where favorable outcomes were observed only in a subgroup of patients. Even though this has been prespecified in the protocol, it should be regarded as no more than a hypothesis generator.


Read also: ACC 2018 | TREAT: Ticagrelor + Fibrinolytics’ Effect on Bleeding.


Outcomes are consistent with other small study outcomes and this benefit seems logical, especially in patients undergoing ACS.

Studies such as the PROVE-IT and the IMPROVE-IT have shown the benefit of intensive care with statins within 7 days after ACS in PCI patients. The present study reduces this benefit even more and starts treatment before revascularization. We could challenge the benefit of this course of action but the fact that there were no adverse effects puts us at ease.

The SECURE-PCI was carried out in 53 centers in Brazil and randomized 4191 patients undergoing ACS assessed with angiography to receive 80mg load of atorvastatin vs placebo prior PCI and 24 hrs. after PCI. Both branches continued with 40 mg atorvastatin after the second dose of medication.


Read also: ACC 2018 | SMART-DATE: 6 Month DAPT Results Suboptimal in ACS.


When looking at the remaining 2710 finally treated with PCI, we find that atorvastatin preloading was associated with a 28% reduction of combined end points, compared to placebo (p=0.02) and a reduction of 32% of MI risk (p=0.04), including a 58% reduction of unrelated MI.

Original title: Effect of loading dose of atorvastatin prior to planned percutaneous coronary intervention on major adverse cardiovascular events in acute coronary syndrome: the SECURE-PCI randomized clinical trial.

Reference: Berwanger O et al. JAMA. 2018; Epub ahead of print.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

We are interested in your opinion. Please, leave your comments, thoughts, questions, etc., below. They will be most welcome.

More articles by this author

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...

EuroPCR 2026 | TAVI and Coronary Artery Disease: FFR-Guided PCI Showed Better Outcomes Than an Angiography-Guided Strategy

In patients undergoing TAVI, the concomitant presence of coronary artery disease continues to generate debate: whether coronary lesions should be treated before, during, or...

EuroPCR 2026 | P2Y12 Inhibitor Monotherapy After Complex PCI in ACS: Results From the NEO-MINDSET COMPLEX Subanalysis

This is a summary of the NEO-MINDSET COMPLEX subanalysis, presented by Dr. Guy Prado at EuroPCR 2026, which evaluated P2Y12 inhibitor monotherapy versus dual...

EuroPCR 2026 | Evolocumab Reduces Cardiovascular Events in Patients With Prior PCI Without Previous Myocardial Infarction: VESALIUS-CV Results

This presentation, delivered by Dr. Brian A. Bergmark and colleagues at EuroPCR 2026, detailed the results of the VESALIUS-CV trial, focusing specifically on the...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

EuroPCR 2026 | MELA Registry: Myval Showed Lower Aortic Regurgitation Rates in Patients With Large Aortic Annuli

This presentation, delivered by Dr. Salvatore Giordano at EuroPCR 2026, detailed the results of the MELA Registry, a multicenter study comparing the performance of...

EuroPCR 2026 | LANDMARK Trial: Two-Year Results Showed Comparable Efficacy Between Myval and Contemporary TAVI Valves

The LANDMARK trial presentation, delivered by Prof. Patrick W. Serruys at EuroPCR 2026, detailed the two-year clinical outcomes of contemporary transcatheter aortic valve implantation...

EuroPCR 2026 | 10-Year Left Main PCI: When Survival Is Similar, Should the Less Invasive Strategy Prevail?

The primary goal of revascularization in left main coronary artery disease (LMCA) is to improve survival. However, debate continues regarding whether, in anatomically suitable...